Effectiveness of mRNA BNT162b2 Vaccine 6 Months after Vaccination among Patients in Large Health Maintenance Organization, Israel

Effectiveness of mRNA BNT162b2 Vaccine 6 Months after Vaccination among Patients in Large Health Maintenance Organization, Israel

Israel experienced a new wave of coronavirus disease during June 2021, six months after implementing a national vaccination campaign. We conducted 3 discrete analyses using data from a large health maintenance organization in Israel to determine whether IgG levels of fully vaccinated persons decreas...

Full description

Bibliographic Details
Main Authors:	Jennifer Kertes, Sharon Baruch Gez, Yaki Saciuk, Lia Supino-Rosin, Naama Shamir Stein, Miri Mizrahi-Reuveni, Anat E. Zohar
Format:	Article
Language:	English
Published:	Centers for Disease Control and Prevention 2022-02-01
Series:	Emerging Infectious Diseases
Subjects:	COVID-19 coronavirus disease severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 coronaviruses viruses
Online Access:	https://wwwnc.cdc.gov/eid/article/28/2/21-1834_article

Similar Items

Effectiveness of BNT162b2 Vaccine against Omicron Variant Infection among Children 5–11 Years of Age, Israel
by: Aharona Glatman-Freedman, et al.
Published: (2023-04-01)

Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021
by: Aharona Glatman-Freedman, et al.
Published: (2021-11-01)

Effectiveness of BNT162b2 Vaccine Booster against SARS-CoV-2 Infection and Breakthrough Complications, Israel
by: Aharona Glatman-Freedman, et al.
Published: (2022-05-01)

Self-Reported and Physiologic Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose
by: Merav Mofaz, et al.
Published: (2022-07-01)

Keratoplasty rejection after messenger RNA vaccine (BNT162b2) for COVID-19
by: Maria Eduarda Andrade e Andrade, et al.
Published: (2022-01-01)

Dynamics of SARS-CoV-2 Antibody Response to CoronaVac followed by Booster Dose of BNT162b2 Vaccine
by: Marcela Helena Gambim Fonseca, et al.
Published: (2022-06-01)

Serum Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 after BNT162b2 Booster Vaccination
by: Rune M. Pedersen, et al.
Published: (2022-06-01)

Syncope following Pfizer BioNTech (bnt162b2) vaccination unmasking Brugada syndrome
by: Mohammad Altermanini, et al.
Published: (2023-08-01)

Favorable Humoral Response to Third Dose of BNT162b2 in Patients Undergoing Hemodialysis
by: Mineaki Kitamura, et al.
Published: (2022-04-01)

Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination
by: Pinja Jalkanen, et al.
Published: (2022-04-01)

The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout
by: Ahmed Zaqout, et al.
Published: (2021-07-01)

Humoral immunity after Pfizer/BioNTech BNT162b2 vaccine in healthcare workers of ASL Roma 2 (Italy)
by: Eliana Giberna, et al.
Published: (2021-10-01)

Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine in Patients with Cardiovascular Disease
by: Hiroyuki Naruse, et al.
Published: (2021-11-01)

Postvaccination COVID-19 among Healthcare Workers, Israel
by: Zohaib Yousaf, et al.
Published: (2021-06-01)

Adverse events of special interest following the use of BNT162b2 in adolescents: a population-based retrospective cohort study
by: Francisco Tsz Tsun Lai, et al.
Published: (2022-12-01)

Impact of Full Vaccination with mRNA BNT162b2 on SARS-CoV-2 Infection: Genomic and Subgenomic Viral RNAs Detection in Nasopharyngeal Swab and Saliva of Health Care Workers
by: Michela Deiana, et al.
Published: (2021-08-01)

Estimating COVID-19 Vaccine Effectiveness for Skilled Nursing Facility Healthcare Personnel, California, USA
by: Monise Magro, et al.
Published: (2022-08-01)

Analysis of Immunization, Adverse Events, and Efficacy of a Fourth Dose of BNT162b2 Vaccine in Health Workers in Mexico, a Pilot Study
by: Maria Elena Romero-Ibarguengoitia, et al.
Published: (2022-07-01)

The Paradox of Israel’s Coronavirus Law
by: Aeyal Gross, et al.

Adjuvants for Coronavirus Vaccines
by: Zhihui Liang, et al.
Published: (2020-11-01)

Seroprevalence of severe acute respiratory syndrome coronavirus 2 immunoglobulin G antibodies among health-care workers prior and after 4–6 weeks of coronavirus disease vaccine administration at tertiary care center of southwest Bihar, India
by: Mukesh Kumar, et al.
Published: (2022-01-01)

Safety and antibody response of recipients who unexpectedly received undiluted prime dose of BNT162b2 COVID-19 vaccine in Taiwan
by: Wang-Huei Sheng, et al.
Published: (2023-01-01)

Multistate Outbreak of SARS-CoV-2 Infections, Including Vaccine Breakthrough Infections, Associated with Large Public Gatherings, United States
by: Radhika Gharpure, et al.
Published: (2022-01-01)

SARS-CoV-2 Vaccination Associated Transverse Myelitis: A Case Report
by: Bhargavi Kumar, et al.
Published: (2022-09-01)

Nationwide Outbreak of Candida auris Infections Driven by COVID-19 Hospitalizations, Israel, 2021–2022
by: Roni Biran, et al.
Published: (2023-07-01)

Psychobehavioral Responses and Likelihood of Receiving COVID-19 Vaccines during the Pandemic, Hong Kong
by: Kin On Kwok, et al.
Published: (2021-07-01)

Efficacy and safety of potential vaccine candidates against coronavirus disease 2019: A systematic review
by: Subodh Kumar, et al.
Published: (2021-01-01)

Mass culling of minks to protect the COVID-19 vaccines: is it rational?
by: R. Frutos, et al.
Published: (2020-11-01)

Histopathologically TMA-like distribution of multiple organ thromboses following the initial dose of the BNT162b2 mRNA vaccine (Comirnaty, Pfizer/BioNTech): an autopsy case report
by: Ryo Kaimori, et al.
Published: (2022-10-01)

Leveraging HIV Program and Civil Society to Accelerate COVID-19 Vaccine Uptake, Zambia
by: Patricia Bobo, et al.
Published: (2022-11-01)

Effect of Heterologous Vaccination Regimen with Ad5-nCoV CanSinoBio and BNT162b2 Pfizer in SARS-CoV-2 IgG Antibodies Titers
by: Maria Elena Romero-Ibarguengoitia, et al.
Published: (2022-03-01)

Development of Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-COV-2) Vaccines
by: Kenneth Ogar Inaku, et al.
Published: (2022-01-01)

SARS-CoV-2 Vaccine Breakthrough by Omicron and Delta Variants, New York, USA
by: Alexander C. Keyel, et al.
Published: (2022-10-01)

SARS-CoV-2 Infection: New Molecular, Phylogenetic, and Pathogenetic Insights. Efficacy of Current Vaccines and the Potential Risk of Variants
by: John Charles Rotondo, et al.
Published: (2021-08-01)

Perception and acceptance of Coronavirus Disease-2019 vaccines among doctors
by: Arun Kumar Yadav, et al.
Published: (2021-01-01)

Age-Dependent Effects of COVID-19 Vaccine and of Healthcare Burden on COVID-19 Deaths, Tokyo, Japan
by: Yura K. Ko, et al.
Published: (2022-09-01)

Review of Progress in New-Coronavirus Detection and Vaccine Research
by: Liu Tongtong
Published: (2023-01-01)

Targeting the conserved coronavirus octamer motif GGAAGAGC is a strategy for the development of coronavirus vaccine
by: Ching-Hung Lin, et al.
Published: (2023-11-01)

SARS-CoV-2 Vaccine Effectiveness against Omicron Variant in Infection-Naive Population, Australia, 2022
by: Lauren E. Bloomfield, et al.
Published: (2023-06-01)

Past as Prologue—Use of Rubella Vaccination Program Lessons to Inform COVID-19 Vaccination
by: Meredith G. Dixon, et al.
Published: (2022-11-01)